Aoxing Pharmaceutical Company, Inc. (AOXG) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Aoxing Pharmaceutical Company, Inc. (AOXG) opera en el sector Healthcare, cotizado por última vez a $ con una capitalización de mercado de 0. Calificado con 49/100 (cauteloso) en potencial de crecimiento, salud financiera e impulso.
Ultimo analisis: 17 mar 2026Aoxing Pharmaceutical Company, Inc. (AOXG) Resumen de Asistencia Médica y Tuberías
Aoxing Pharmaceutical Company, Inc. is a specialty pharmaceutical company based in China, focusing on narcotic, pain-management, and addiction treatment products, including both herbal and synthetic drugs. With a negative P/E ratio and high gross margin, the company navigates a competitive landscape while developing new pain and addiction treatments.
Tesis de Inversión
Aoxing Pharmaceutical Company, Inc. presents a high-risk, high-reward investment profile. The company's focus on the Chinese market for pain management and addiction treatment offers potential growth, especially with its pipeline of drugs like Oxycodone/Acetaminophen and Buprenorphine/Naloxone. However, the company's negative P/E ratio of -183.91 and a negative profit margin of -79.5% raise concerns about its financial stability. Successful navigation of clinical trials and regulatory approvals for its pipeline drugs are key catalysts. Investors should closely monitor the company's progress in these areas, as well as its ability to improve profitability and manage its high beta of -59.16.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Market Cap of $0.00B indicates a micro-cap company with limited resources and higher volatility.
- P/E Ratio of -183.91 reflects the company's current unprofitability, requiring careful evaluation of future earnings potential.
- Gross Margin of 88.1% suggests strong pricing power on existing products, but this needs to translate into overall profitability.
- Beta of -59.16 indicates an inverse correlation with the market, which is unusual and may be due to the stock's illiquidity or unique business model.
- Focus on narcotic, pain-management, and addiction treatment pharmaceutical products in China, a market with significant unmet needs and growth potential.
Competidores y Pares
Fortalezas
- Specialized focus on pain management and addiction treatment.
- Established manufacturing capabilities in China.
- Pipeline of drugs in development.
- Existing distribution network within China.
Debilidades
- Negative profitability and high debt levels.
- Reliance on a single geographic market (China).
- Limited financial resources for R&D and marketing.
- OTC Other tier indicates higher risk.
Catalizadores
- Upcoming: Regulatory approval and commercialization of Oxycodone and Acetaminophen tablets and capsules for pain management.
- Upcoming: Positive results from Phase III clinical trials for Buprenorphine/Naloxone in treating opioid dependence.
- Ongoing: Expansion of distribution network within China to reach more patients.
- Ongoing: Increased government support for domestic pharmaceutical companies in China.
- Ongoing: Growing demand for pain management and addiction treatment products in China.
Riesgos
- Potential: Failure to obtain regulatory approvals for pipeline drugs.
- Potential: Intense competition from established pharmaceutical companies.
- Ongoing: Pricing pressures from generic drug manufacturers.
- Ongoing: Dependence on the Chinese market and regulatory environment.
- Potential: Product liability claims and lawsuits.
Oportunidades de crecimiento
- Expansion of Product Portfolio: Aoxing's pipeline of drugs in development, including Oxycodone/Acetaminophen and Buprenorphine/Naloxone, represents a significant growth opportunity. Successful completion of clinical trials and regulatory approvals could lead to new revenue streams and market share gains. The market for pain management and addiction treatment is substantial, with the global market estimated to reach billions of dollars in the coming years. Timeline: 2-5 years for regulatory approvals.
- Geographic Expansion within China: While Aoxing primarily operates in China, there is potential to expand its geographic reach within the country. Targeting specific regions with high demand for pain management and addiction treatment products could drive revenue growth. This expansion could involve establishing new distribution channels and partnerships. Timeline: 1-3 years.
- Strategic Partnerships and Acquisitions: Aoxing could pursue strategic partnerships or acquisitions to expand its product portfolio, geographic reach, or technological capabilities. Collaborating with other pharmaceutical companies or research institutions could accelerate the development and commercialization of new drugs. Timeline: Ongoing.
- Increased Investment in Research and Development: Aoxing could increase its investment in research and development to discover and develop novel drugs for pain management and addiction treatment. This could involve conducting preclinical and clinical studies, as well as collaborating with academic institutions and research organizations. Timeline: Long-term, 5+ years.
- Leveraging Government Support for Domestic Pharmaceutical Companies: The Chinese government is actively supporting the growth of domestic pharmaceutical companies through various policies and initiatives. Aoxing can leverage these policies to access funding, streamline regulatory approvals, and gain a competitive advantage. Timeline: Ongoing.
Oportunidades
- Expanding into new geographic markets.
- Developing new drug formulations and delivery methods.
- Partnering with other pharmaceutical companies.
- Leveraging government support for domestic pharmaceutical companies.
Amenazas
- Intense competition from established pharmaceutical companies.
- Stringent regulatory requirements.
- Pricing pressures from generic drug manufacturers.
- Potential product liability claims.
Ventajas competitivas
- Proprietary drug formulations and intellectual property.
- Established distribution network within China.
- Expertise in developing and manufacturing narcotic and pain-relief medications.
- Regulatory approvals for its existing products.
Acerca de AOXG
Aoxing Pharmaceutical Company, Inc., headquartered in Shijiazhuang, China, is a specialty pharmaceutical company dedicated to the research, development, manufacture, and distribution of pharmaceutical products. The company primarily operates in the People's Republic of China, focusing on narcotic, pain-management, and addiction treatment medications. Aoxing’s product portfolio includes Zhongtong'an, a herbal capsule designed for oral and dental pain relief, and Yiqi Qiangshen Granule, an over-the-counter herbal supplement aimed at tonifying qi, empowering the body, and promoting blood circulation. Additionally, the company manufactures Tilidine hydrochloride, a synthetic narcotic analgesic tablet used for moderate to severe pain relief. Further expanding their offerings, Aoxing has several products in development, including Oxycodone and Acetaminophen tablets and capsules, which have completed clinical trials for treating acute and chronic pain. They are also developing Buprenorphine/Naloxone, a sublingual tablet for opioid dependence treatment, which has completed Phase II clinical trials, and Tilidine/Naloxone, a compound capsule in Phase II clinical trials for acute and chronic pain management. Originally known as China Aoxing Pharmaceutical Company, Inc., the company rebranded to Aoxing Pharmaceutical Company, Inc. in March 2010, solidifying its commitment to advancing pharmaceutical solutions.
Qué hacen
- Researches and develops pharmaceutical products focused on pain management, addiction treatment, and related areas.
- Manufactures narcotic and non-narcotic pain relief medications.
- Produces herbal extraction products for pain relief and general health improvement.
- Distributes its pharmaceutical products primarily within the People's Republic of China.
- Conducts clinical trials for new drug candidates, including treatments for opioid dependence.
- Markets both prescription and over-the-counter (OTC) medications.
Modelo de Negocio
- Develops and manufactures pharmaceutical products.
- Sells prescription and OTC medications through distributors and directly to healthcare providers.
- Generates revenue from the sale of its proprietary drug formulations.
- Invests in research and development to create new products and improve existing ones.
Contexto de la Industria
Aoxing Pharmaceutical Company, Inc. operates within the specialty and generic drug manufacturing industry, a sector characterized by intense competition and stringent regulatory oversight. The Chinese pharmaceutical market is experiencing rapid growth, driven by an aging population and increasing healthcare spending. However, domestic companies face challenges from international players and evolving regulatory standards. Aoxing's focus on pain management and addiction treatment positions it in a niche market with specific needs, but also heightened regulatory scrutiny. Competitors like AREVF and CWWBF also operate in this space.
Clientes Clave
- Hospitals and clinics throughout China.
- Pharmacies and drug stores.
- Patients seeking pain relief and addiction treatment.
- Healthcare providers prescribing medications.
Finanzas
Gráfico e información
Precio de la acción de Aoxing Pharmaceutical Company, Inc. (AOXG): Price data unavailable
Últimas noticias
No hay noticias recientes disponibles para AOXG.
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para AOXG.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para AOXG.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de AOXG en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Liderazgo: Zhenjiang Yue
CEO
Zhenjiang Yue serves as the CEO of Aoxing Pharmaceutical Company, Inc. He is responsible for overseeing the company's overall strategy, operations, and financial performance. His leadership is crucial in guiding Aoxing through the complex regulatory landscape and competitive market in China. He manages a workforce of 346 employees, focusing on research, development, and manufacturing of pharmaceutical products.
Historial: Under Zhenjiang Yue's leadership, Aoxing Pharmaceutical Company has focused on developing and commercializing pain management and addiction treatment products. Key milestones include advancing clinical trials for pipeline drugs such as Oxycodone/Acetaminophen and Buprenorphine/Naloxone. The company has also maintained its presence in the Chinese pharmaceutical market despite financial challenges.
Información del mercado OTC de AOXG
The OTC Other tier represents the lowest tier of the OTC market, indicating that Aoxing Pharmaceutical Company, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited or no financial disclosure, making it difficult for investors to assess their financial health and viability. Investing in OTC Other stocks carries significantly higher risk compared to stocks listed on major exchanges like the NYSE or NASDAQ due to the lack of regulatory oversight and transparency.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited financial disclosure and transparency.
- Low trading volume and liquidity.
- Higher risk of fraud and manipulation.
- Potential for delisting or suspension of trading.
- Limited regulatory oversight.
- Verify the company's registration and legal status.
- Obtain and review any available financial statements.
- Assess the company's business model and competitive landscape.
- Evaluate the management team's experience and track record.
- Understand the risks associated with investing in OTC Other stocks.
- Consult with a qualified financial advisor.
- Check for any regulatory actions or legal disputes.
- Existence of a physical headquarters and operational facilities.
- Presence of a functional website and contact information.
- Patents or intellectual property related to its products.
- Partnerships with reputable organizations or institutions.
- Active engagement with investors and the public.
Lo Que los Inversores Preguntan Sobre Aoxing Pharmaceutical Company, Inc. (AOXG)
¿Cuáles son los factores clave para evaluar AOXG?
Aoxing Pharmaceutical Company, Inc. (AOXG) actualmente tiene una puntuación IA de 49/100, indicando puntuación baja. Fortaleza clave: Specialized focus on pain management and addiction treatment.. Riesgo principal a monitorear: Potential: Failure to obtain regulatory approvals for pipeline drugs.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de AOXG?
AOXG actualmente puntúa 49/100 (Grado D) en el MoonshotScore, lo que sugiere calificación baja. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de AOXG?
Los precios de AOXG se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre AOXG?
La cobertura de analistas para AOXG incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en AOXG?
Las categorías de riesgo para AOXG incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Failure to obtain regulatory approvals for pipeline drugs.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de AOXG?
La relación P/E para AOXG compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está AOXG sobrevalorada o infravalorada?
Determinar si Aoxing Pharmaceutical Company, Inc. (AOXG) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de AOXG?
Aoxing Pharmaceutical Company, Inc. (AOXG) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Information is based on available data as of 2026-03-17.
- OTC Other stocks carry significant risks and require thorough due diligence.
- Financial data may be limited or unaudited.